CEVEC and Catalent Pharma Solutions Offer Joint Cell Line Development Service

(PresseBox) ( Cologne, Germany, )
CEVEC Pharmaceuticals, the German developer of a novel, market leading human protein expression system derived from amniocytes, and Catalent Pharma Solutions, a leading global drug development and delivery solutions provider, announced today a joint commercial cell line development service for pharma and biotech customers worldwide. The offering combines the benefits of CEVEC's human cell line, CAP-Technology, with Catalent's unique GPEx® (Gene Product Expression) Technology to generate high expressing stable human cell lines in a much shorter timeframe than traditional methods.

"We are very pleased to be working with Catalent and their truly unique technology to generate stable lines" said Dr. Rainer Lichtenberger, CEO of CEVEC. "Several months of testing convincingly showed combining CAP cells and GPEx technology is a very powerful approach. We achieved yields exceeding 3 g/L for a very complex protein produced in our human production cell lines in a very short time frame" added Wolfgang Kintzel, Managing Director and CCO of CEVEC. "The combined offering is a very compelling value proposition for clients looking to outsource cell line development and potential downstream cGMP upscaling while looking for the highest quality using a human cell line."

"Catalent has been collaborating with customers and suppliers to accelerate biologics development for more than ten years. This exciting collaboration with CEVEC will offer biotech companies developing recombinant proteins and antibodies the advantage of two technologies in one system, enabling them to get a clone candidate in less than 5 months and significantly reducing their time to clinic" stated Scott Houlton, President, Development & Clinical Services. "The GPEx technology has been used to express more than 380 different molecules and our integrated development and manufacturing services allow us to take our customers through their clinical trials in the fastest, most cost effective manner."

For more information regarding GPEx® technology and Catalent's biologics offering, please visit Catalent's web site at www.catalent.com.

About Catalent Pharma Solutions

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 8,000 people at 24 facilities worldwide and in fiscal year 2010 generated more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, NJ, USA.

Catalent. more products. better treatments. reliably supplied.™
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.